Sevoflurane for Treatment-Resistant Depression

• Status: Not yet recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai First Maternity and Infant Hospital
• Collaborator: Shanghai Pudong New Area Mental Health Center
• Treatments: Sevoflurane

Criteria

Inclusion Criteria:

1. age 18-65 years

2. meeting DSM-V criteria for major depressive disorder

3. a pretreatment score ≥17 on HDRS-17

4. meeting criteria for TRD, defined as having had at least two adequate dose-duration antidepressant medication failures in the current depressive episode.

5. current treatment drugs were stably used for at least 4 weeks

Exclusion Criteria:

1. MDD with psychosis, e.g., bipolar disorder, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, panic disorder, et al

2. Drug, tobacco or alcohol abuse

3. active suicidal intention

4. previous administration of NMDA receptor antagonists (e.g., ketamine)

5. previous (<6 weeks prior) or ongoing treatment with electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)

6. pregnancy or breastfeeding

7. morbidly obese, BMI>35kg/m2

8. other diseases that could interfere with the results